focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLunglife Ai Regulatory News (LLAI)

Share Price Information for Lunglife Ai (LLAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.40 (-1.91%)
Spread: 1.00 (5.00%)
Open: 20.90
High: 20.90
Low: 20.50
Prev. Close: 20.90
LLAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Dec 2022 14:37

RNS Number : 9546I
LungLife AI, INC
07 December 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

USU5500L1045

Issuer Name

LUNGLIFE AI, INC.

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

Other

Comments

Movement out of discretionary management

3. Details of person subject to the notification obligation

Name

Investec Wealth & Investment Limited

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

06-Dec-2022

6. Date on which Issuer notified

07-Dec-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.960000

0.000000

4.960000

1265289

Position of previous notification (if applicable)

5.040000

0.000000

5.040000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Ordinary Shares USU5500L1045

1265289

4.960000

Sub Total 8.A

1265289

4.960000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Investec Wealth & Investment Limtied

Investec Wealth & Investment Limtied

4.960000

4.960000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-Dec-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFZMGZDNDGZZM
12
Date   Source Headline
15th May 20247:00 amRNSBlock Listing Six Monthly Return
2nd May 20244:04 pmRNSHolding(s) in Company
25th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
17th Apr 20247:00 amRNSPresentation at NCI's EDRN Meeting
4th Apr 20247:00 amRNSPreliminary Audited Results
27th Mar 20247:00 amRNSNotice of Results
26th Mar 20241:49 pmRNSHolding(s) in Company
25th Mar 202410:33 amRNSHolding(s) in Company
22nd Mar 20249:39 amRNSAdmission of New Shares & PDMR Dealing
22nd Mar 20248:21 amRNSAdmission of New Shares & PDMR Dealing
21st Mar 20242:05 pmRNSResult of Special Meeting
6th Mar 20245:35 pmRNSPosting of Circular and Notice of Special Meeting
5th Mar 20247:00 amRNSResults of Placing and Subscription
4th Mar 20244:56 pmRNSProposed equity raise of approximately £1.8m
2nd Jan 20247:00 amRNSSuccessful validation study results for LungLB®
15th Nov 20237:00 amRNSBlock Listing Six Monthly Return
28th Sep 20237:00 amRNSClinical validation study update
14th Aug 20231:32 pmRNSDirector share purchases
8th Aug 20237:00 amRNSHalf-year Report
3rd Aug 20237:00 amRNSNotice of Results
6th Jun 20237:00 amRNSLungLB® study published in peer-reviewed journal
23rd May 20237:00 amRNSEnrolment completed for LungLB® validation study
15th May 20237:00 amRNSBlock Listing Six Monthly Return
4th May 20235:49 pmRNSResult of AGM
2nd May 20237:00 amRNSConfirmation of AGM
6th Apr 20233:50 pmRNSPublication of Annual Report & Notice of AGM
14th Mar 20237:00 amRNSAppointment of Joint Broker
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
7th Mar 20237:00 amRNSHealth economics publication
27th Feb 20237:00 amRNSData on cost-effectiveness of LungLB®
20th Feb 20237:00 amRNSPreliminary results for year ended 31 Dec 2022
8th Feb 20237:00 amRNSNotice of Results
7th Dec 20222:37 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSFinal Pricing Determination
30th Nov 20227:00 amRNSTotal Voting Rights
15th Nov 20227:00 amRNSBlock Listing Six Monthly Return
3rd Nov 20227:00 amRNSDirector share purchases
17th Oct 20227:00 amRNSParticipation in National Cancer Institute’s EDRN
26th Sep 20227:00 amRNSHalf-year Report
9th Sep 20227:00 amRNSNotice of Results
2nd Sep 20227:00 amRNSNew York State approval for commercial testing
16th May 20227:00 amRNSBlock Listing Six Monthly Return
11th May 20223:17 pmRNSResult of AGM
8th Apr 20227:00 amRNSPublication of AR and Accounts & Notice of AGM
28th Mar 20227:00 amRNSPreliminary Results
17th Mar 20227:00 amRNSVA sites in validation study; SAB appointment
2nd Feb 20227:00 amRNSFirst patient enrolment for LungLB® study
4th Jan 20227:00 amRNSCPT® Code granted by American Medical Association
19th Nov 20217:00 amRNSLungLife AI Laboratory achieves CAP accreditation
10th Nov 20217:00 amRNSBlock Listing Application
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.